Indivior 관리

관리 기준 확인 1/4

Indivior CEO는 Mark Crossley, Jun2020 에 임명되었습니다 의 임기는 2.33 년입니다. 총 연간 보상은 $ 5.11M, 15.2% 로 구성됩니다. 15.2% 급여 및 84.8% 보너스(회사 주식 및 옵션 포함). 는 MX$ 27.86M 가치에 해당하는 회사 주식의 0.065% 직접 소유합니다. 27.86M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 2.4 년입니다.

주요 정보

Mark Crossley

최고 경영자

US$5.1m

총 보상

CEO 급여 비율	15.2%
CEO 임기	2.3yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	2.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Mark Crossley 의 보수는 Indivior 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2022	n/a	n/a	US$152m
Mar 31 2022	n/a	n/a	US$166m
Dec 31 2021	US$5m	US$775k	US$205m
Sep 30 2021	n/a	n/a	US$156m
Jun 30 2021	n/a	n/a	US$139m
Mar 31 2021	n/a	n/a	US$95m
Dec 31 2020	US$761k	US$675k	-US$148m
Sep 30 2020	n/a	n/a	-US$190m
Jun 30 2020	n/a	n/a	-US$152m
Mar 31 2020	n/a	n/a	-US$95m
Dec 31 2019	US$1m	US$528k	US$134m
Sep 30 2019	n/a	n/a	US$213m
Jun 30 2019	n/a	n/a	US$254m
Mar 31 2019	n/a	n/a	US$248m
Dec 31 2018	US$551k	US$494k	US$275m
Sep 30 2018	n/a	n/a	US$106m
Jun 30 2018	n/a	n/a	US$67m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$2m	US$413k	US$58m

보상 대 시장: Mark 의 총 보상 ($USD 5.11M )은 MX 시장( $USD 699.19K ).

보상과 수익: Mark 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Mark Crossley

2.3yrs

테뉴어

US$5,110,000

보상

Mr. Mark Crossley has been Chief Executive Officer of Indivior PLC since June 29, 2020 and served as its Chief Financial and Operations Officer since July 29, 2019 until June 29, 2020. He has a wealth of f...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Crossley	CEO & Executive Director	2.3yrs	US$5.11m	0.065% MX$ 27.9m
Ryan Preblick	CFO & Executive Director	2.3yrs	US$1.26m	0.020% MX$ 8.7m
Christian Heidbreder	Chief Scientific Officer	no data	데이터 없음	0.067% MX$ 28.8m
Jason Thompson	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Cynthia Cetani	Chief Integrity & Compliance Officer	4yrs	데이터 없음	0.026% MX$ 11.2m
Jeffrey Burris	Chief Legal Officer	less than a year	데이터 없음	데이터 없음
Jon Fogle	Chief Human Resources Officer	8yrs	데이터 없음	0.044% MX$ 18.7m
Richard Simkin	Chief Commercial & Strategy Officer	no data	데이터 없음	0.064% MX$ 27.1m
Hillel West	Chief Manufacturing & Supply Officer	2.7yrs	데이터 없음	데이터 없음
Nina DeLorenzo	Chief Global Impact Officer	less than a year	데이터 없음	데이터 없음
Kathryn Hudson	Company Secretary	7.3yrs	데이터 없음	0.020% MX$ 8.6m

2.5yrs

평균 재임 기간

경험이 풍부한 관리: INDV N 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Crossley	CEO & Executive Director	5.7yrs	US$5.11m	0.065% MX$ 27.9m
Ryan Preblick	CFO & Executive Director	1.9yrs	US$1.26m	0.020% MX$ 8.7m
Graham Hetherington	Independent Non-Executive Chairman	2.9yrs	US$372.37k	0.011% MX$ 4.9m
Daniel Phelan	Senior Independent Director	7.9yrs	US$141.10k	0.016% MX$ 6.8m
Juliet Thompson	Independent Non-Executive Director	1.6yrs	US$87.07k	데이터 없음
Peter James Bains	Independent Non-Executive Director	3.2yrs	US$115.10k	0.0078% MX$ 3.3m
Barbara Ryan	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Mark Stejbach	Independent Non-Executive Director	1.6yrs	US$83.70k	0.0060% MX$ 2.6m
Jerome Lande	Non-Executive Director	1.6yrs	US$83.70k	0.000050% MX$ 21.3k
Lorna Parker	Independent Non-Executive Director	7.9yrs	US$106.02k	0.0038% MX$ 1.6m
A. McLellan	Independent Non-Executive Director	7.9yrs	US$108.30k	0.0011% MX$ 469.0k
Joanna Le Couilliard	Independent Non-Executive Director	1.6yrs	US$78.54k	데이터 없음

2.4yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: INDV N 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Indivior 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Jerome Lande to Step Down from the Board of Indivior plc

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Announces Board Committee Changes

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC Announces Executive Changes

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Recent updates

Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment

Jerome Lande to Step Down from the Board of Indivior plc

Oaktree Capital Sends a Letter to Indivior PLC

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Indivior plc Reconfirms Earnings Guidance for 2024

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Investor sentiment deteriorated over the past week

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder

First quarter 2022 earnings released: EPS: US$0.06 (vs US$0.11 in 1Q 2021)

Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022

High number of new directors

Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC

Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

Indivior PLC, Annual General Meeting, May 05, 2022

Full year 2021 earnings released: EPS: US$0.28 (vs US$0.20 loss in FY 2020)

Indivior PLC, Annual General Meeting, May 05, 2022

Chief Human Resources Officer recently sold Mex$12m worth of stock

Chief Commercial & Strategy Officer recently sold Mex$22m worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Indivior PLC Provides Revenue Guidance for the Year 2022

Indivior PLC to Report Fiscal Year 2021 Results on Feb 16, 2022

Indivior PLC Announces Results from Buprenorphine-Fentanyl Interaction Study in PLOS ONE

Third quarter 2021 earnings released: EPS US$0.04 (vs US$0.014 in 3Q 2020)

Independent Non-Executive Chairman recently bought Mex$1.4m worth of stock

Second quarter 2021 earnings released: EPS US$0.08 (vs US$0.025 in 2Q 2020)

Indivior PLC Raises Revenue Guidance for the Fiscal Year 2021

Indivior PLC Presents New Data at the College on Problems of Drug Dependence 2021 Annual Conference